JP2019528302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528302A5 JP2019528302A5 JP2019511500A JP2019511500A JP2019528302A5 JP 2019528302 A5 JP2019528302 A5 JP 2019528302A5 JP 2019511500 A JP2019511500 A JP 2019511500A JP 2019511500 A JP2019511500 A JP 2019511500A JP 2019528302 A5 JP2019528302 A5 JP 2019528302A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- amino
- acceptable salt
- methylureido
- dimethoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 17
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 10
- -1 6- (3- (2,6-dichloro-3,5-dimethoxyphenyl) -1-methylureido) pyrimidin-4-yl Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 claims 6
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims 3
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 3
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 229950001573 abemaciclib Drugs 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 229960004390 palbociclib Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 229950003687 ribociclib Drugs 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims 1
- BBUVDDPUURMFOX-SAABIXHNSA-N AMG-925 Chemical compound C1C[C@@H](C)CC[C@@H]1N1C2=NC(NC=3N=C4CCN(CC4=CC=3)C(=O)CO)=NC=C2C2=CC=NC=C21 BBUVDDPUURMFOX-SAABIXHNSA-N 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378455P | 2016-08-23 | 2016-08-23 | |
| US62/378,455 | 2016-08-23 | ||
| PCT/US2017/048183 WO2018039324A1 (en) | 2016-08-23 | 2017-08-23 | Combination therapies for the treatment of hepatocellular carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528302A JP2019528302A (ja) | 2019-10-10 |
| JP2019528302A5 true JP2019528302A5 (enExample) | 2020-09-24 |
| JP7190425B2 JP7190425B2 (ja) | 2022-12-15 |
Family
ID=59772765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511500A Active JP7190425B2 (ja) | 2016-08-23 | 2017-08-23 | 肝細胞癌の治療のための併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190175598A1 (enExample) |
| EP (1) | EP3503923B1 (enExample) |
| JP (1) | JP7190425B2 (enExample) |
| KR (1) | KR102466192B1 (enExample) |
| CN (1) | CN109803684B (enExample) |
| AU (1) | AU2017315357B2 (enExample) |
| BR (1) | BR112019003722A2 (enExample) |
| CA (1) | CA3034875C (enExample) |
| ES (1) | ES2966469T3 (enExample) |
| IL (1) | IL264950B2 (enExample) |
| MX (1) | MX2019002115A (enExample) |
| RU (1) | RU2769251C2 (enExample) |
| SG (1) | SG11201901472TA (enExample) |
| WO (1) | WO2018039324A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| CA3100144C (en) | 2018-05-14 | 2023-10-03 | Pfizer Inc. | Oral solution formulation of palbociclib in malic or lactic acid buffer |
| TW202128174A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| WO2021230886A1 (en) * | 2020-05-15 | 2021-11-18 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an fgfr4 inhibitor |
| KR20250003965A (ko) | 2022-05-30 | 2025-01-07 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 암 치료용 약학적 조합 및 약학적 조성물 |
| CN120417928A (zh) * | 2023-11-30 | 2025-08-01 | 石药集团中奇制药技术（石家庄）有限公司 | 联合治疗肿瘤的药物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
| DK1252155T3 (da) | 2000-01-18 | 2005-04-04 | Aventis Pharma Inc | Ethanolsolvat af (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-on |
| AU2001226346A1 (en) | 2000-01-18 | 2001-07-31 | Aventis Pharmaceuticals Inc. | Pseudopolymorph of |
| US20050004007A1 (en) | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| JP4291696B2 (ja) | 2002-01-22 | 2009-07-08 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン |
| CA2532965C (en) | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| KR101345002B1 (ko) | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| KR101346886B1 (ko) | 2005-01-21 | 2014-01-02 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| US20080161355A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| JP2009542608A (ja) | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2046330A2 (en) | 2006-07-14 | 2009-04-15 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008009954A1 (en) | 2006-07-21 | 2008-01-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| ES2554513T3 (es) * | 2008-05-23 | 2015-12-21 | Novartis Ag | Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| US20130035336A1 (en) * | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| HRP20161092T1 (hr) | 2010-10-25 | 2016-10-21 | G1 Therapeutics, Inc. | Cdk inhibitori |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| MY161199A (en) | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| ES2610931T3 (es) | 2011-07-01 | 2017-05-04 | Novartis Ag | Terapia de combinación |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| WO2014097125A1 (en) | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| WO2014144326A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of normal cells during chemotherapy |
| MX378263B (es) * | 2013-08-14 | 2025-03-10 | Novartis Ag | Terapia de combinación para el tratamiento del cáncer. |
| CN110354128A (zh) * | 2013-10-18 | 2019-10-22 | 卫材R&D管理有限公司 | 嘧啶fgfr4抑制剂 |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
| US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| CA2982562C (en) * | 2015-04-14 | 2023-06-13 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
-
2017
- 2017-08-23 IL IL264950A patent/IL264950B2/en unknown
- 2017-08-23 BR BR112019003722A patent/BR112019003722A2/pt not_active Application Discontinuation
- 2017-08-23 US US16/324,643 patent/US20190175598A1/en not_active Abandoned
- 2017-08-23 CA CA3034875A patent/CA3034875C/en active Active
- 2017-08-23 AU AU2017315357A patent/AU2017315357B2/en active Active
- 2017-08-23 MX MX2019002115A patent/MX2019002115A/es unknown
- 2017-08-23 EP EP17761701.6A patent/EP3503923B1/en active Active
- 2017-08-23 KR KR1020197008327A patent/KR102466192B1/ko active Active
- 2017-08-23 CN CN201780062334.3A patent/CN109803684B/zh active Active
- 2017-08-23 RU RU2019108259A patent/RU2769251C2/ru active
- 2017-08-23 WO PCT/US2017/048183 patent/WO2018039324A1/en not_active Ceased
- 2017-08-23 SG SG11201901472TA patent/SG11201901472TA/en unknown
- 2017-08-23 JP JP2019511500A patent/JP7190425B2/ja active Active
- 2017-08-23 ES ES17761701T patent/ES2966469T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528302A5 (enExample) | ||
| US20050209250A1 (en) | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | |
| US6432989B1 (en) | Use of CRF antagonists to treat circadian rhythm disorders | |
| RU2019108259A (ru) | Комбинированная терапия для лечения гепатоцеллюлярной карциномы | |
| CA2450777C (en) | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia | |
| CN101671336B (zh) | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 | |
| JP2020504136A5 (enExample) | ||
| US20100009934A1 (en) | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders | |
| TW201032806A (en) | Hsp90 inhibitor combinations | |
| KR101292508B1 (ko) | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도 | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| AU6669500A (en) | Use of corticotropin releasing factor antagonists and related compositions | |
| AU2008276451A1 (en) | Treatments of B-cell proliferative disorders | |
| CN105294682A (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
| RU2019132893A (ru) | Комбинированная терапия для лечения рака молочной железы | |
| US20210052528A1 (en) | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment | |
| CN108430510B (zh) | 与中性肽链内切酶的抑制剂（NEP抑制剂）和/或血管紧张素AII拮抗剂组合的可溶性鸟苷酸环化酶（sGC）的刺激剂和/或活化剂及其用途 | |
| RU2013110124A (ru) | Комбинированная противораковая терапия | |
| JP2016537384A5 (enExample) | ||
| ES2366116T3 (es) | Formulación farmacéutica que comprende melatonina. | |
| JP2005527583A5 (enExample) | ||
| JP2004501153A5 (enExample) | ||
| CN103554111A (zh) | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 | |
| JP2007517854A (ja) | Ｃｒｆアンタゴニスト及び５−ｈｔ１ｂ受容体アンタゴニストの組み合わせ | |
| RU2021106904A (ru) | КОМБИНАЦИИ ИНГИБИТОРОВ TGFβ И ИНГИБИТОРОВ CDK ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |